Drs. Gurbakhash Kaur and Danai Dima discuss next-gen CAR T and bispecific therapies for myeloma, including agents for extramedullary disease and GPRC5D targets.

In this Editor’s Special of The HemOnc Pulse, Tycel Phillips, MD, joins an editor of Blood Cancers Today to break down the latest research in B-cell non-Hodgkin lymphoma presented at the 2025 ASCO Annual Meeting. The conversation spans follicular lymphoma, CLL, mantle cell lymphoma, and large B-cell lymphoma, covering key insights on BTK/BCL2 inhibitors, bispecifics, CAR T-cell therapy, and more.

Hematologist-oncologist Dr. Alexey Danilov shares expert insights on chronic lymphocytic leukemia, highlighting unmet needs in immune management, the challenges of Richter’s transformation, and promising data on BTK degraders for double-refractory patients.

Saad Usmani, MD, MBA leads an in-depth discussion with a panel of leading myeloma experts; Dr. Caitlin Costello, Dr. Binod Dhakal, Dr. Pete Voorhees, and Dr. Shambavi Richard on the evolving landscape of frontline multiple myeloma treatment. The conversation covers the rationale behind quadruplet therapy, the integration of minimal residual disease as a response-adaptive strategy, and shifting perspectives on transplant eligibility and timing. Drawing on recent clinical trial data and personal clinical experience, the panel explores how these advancements are influencing treatment decisions and improving long-term outcomes for patients with newly diagnosed myeloma.

In this Editor’s Special of The HemOnc Pulse, Blood Cancers Today Managing Editor, Nichole Tucker speaks with Amir Fathi, MD, of Massachusetts General Hospital, about key updates in AML from ASCO 2025. The discussion centers on a phase 2 study of an all-oral regimen—decitabine and cedazuridine plus venetoclax—for patients with newly diagnosed AML who are unfit for intensive induction.

Dr. Fathi discusses the potential for these more convenient therapies to shift treatment into the outpatient setting while maintaining effectiveness. He also shares insights on promising triplet regimens incorporating targeted therapies and highlights the need for new strategies for patients with resistant disease subtypes, such as TP53-mutated or venetoclax-refractory AML.

Looking ahead, Dr. Fathi previews anticipated data from menin inhibitor trials and the phase 3 Quantum Wild study. This episode is a must-listen for clinicians and researchers interested in the future of AML care.

In this episode of The Hem Onc Pulse, Dr. Rahul Banerjee is joined by Dr. Michelle Longmire, CEO and co-founder of Medable, for a compelling discussion on drug accessibility in cancer care. Together, they explore how decentralized clinical trials and digital tools can help bridge the gap between cutting-edge therapies and the patients who need them most. Dr. Longmire shares how Medable is expanding access to clinical research, particularly in rural and underserved communities, by reimagining how trials are conducted.

The conversation also examines the systemic and financial challenges that often prevent patients from accessing approved cancer therapies—even after regulatory success. With an eye toward equity, Drs. Banerjee and Longmire unpack the barriers in traditional oncology care and highlight innovative, patient-centered approaches that promise a more inclusive future.

Tune in for a thought-provoking look at the intersection of innovation, policy, and compassion in cancer treatment access.

In this HemOnc Pulse Live! edition of podcast, Dr. Mehdi Hamadani leads a comprehensive panel discussion on controversies and unanswered questions in the treatment of aggressive non-Hodgkin lymphoma. Dr. Hamadani is joined by Drs. Timothy Fenske, Madiha Iqbal, Urshila Durani, and Mohamed Kharfan-Dabaja.

In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology’s hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn’t just helpful—it’s lifesaving.

In this special episode of our podcast, recorded live at HemOnc Pulse Live in Austin, Texas on May 2–3, 2025, leading experts tackle some of the most pressing controversies in the management of myelodysplastic syndromes. Moderated by Naval Daver, MD, this dynamic panel discussion brings together top thought leaders in hematologic malignancies to debate evolving treatment standards, diagnostic challenges, and the integration of emerging therapies in clinical practice.

In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial’s rationale, design, and real-world implications for patients with relapsed or refractory disease.

Tune in to hear expert perspectives on unmet needs in late-line myeloma care, emerging toxicity profiles, and the future of dual-targeted immunotherapy.